DNLI · Denali Therapeutics Inc.

Track DNLI — free

$24.95 -0.74 (-2.88%) At close · Aug 20

Market Cap

$4.02B

159.85M

Up next

Next earnings call

Dec 23, 2026 Est · unconfirmed · in 18 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed Aug 6, 2026

Equibles Rating

blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Weak Quant / Vol High

Market backdrop VIX 14.9 · calm Equity put/call 0.52

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +22%

above

Price vs 50-day avg +3%

above

RSI (14) 54

neutral

MACD trend Positive

52-week position 84%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Strong

1-month return +7%

trailing

6-month return +18%

trailing

YTD return +51%

this year

Relative strength +7%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $24 › 200d $20 — 50d above 200d

Institutional flow Accumulating

+8% holders QoQ · +54 funds added

Insider flow Distributing

Net -$71.6K over 90 days · 100% sells

Short interest Rising

10.91% of float · ▲ +8.7% MoM · 12.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

293 holders — near 3-yr high, broad support

Squeeze score 70

elevated · 0–100

Fundamentals

Weak

EPS growth −16%

Y/Y

Free cash flow $-422.1M

Balance sheet $205.3M

net cash

Quant / Vol

risk profile

High

Volatility 57%

annualized · 1-yr

Max drawdown −20%

past year

ATR 4.0%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the 8-K filed Aug 6, 2026

AVLAYAH net product revenue · third quarter 2026 Initiated $10M – $12M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy

0 · 4 · 3

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+22% Bullish

Price vs 50-day avg

+3% Bullish

RSI (14)

54 Neutral

MACD trend

Positive Bullish

52-week position

84% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50d $24 › 200d $20 — 50d above 200d

Institutional flow Accumulating

+8% holders QoQ · +54 funds added

Insider flow Distributing

Net -$71.6K over 90 days · 100% sells

Short interest Rising

10.91% of float · ▲ +8.7% MoM · 12.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

293 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $13 Now $25 · 84% Range high $27

vs 200-day avg +22% vs 50-day avg +3%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
DNLI Denali Therapeutics Inc. this stock	$4.02B	+51.1%	—	—	10.9%
ONC BeOne Medicines Ltd.	$557.05B	+21.5%	+22179.2%	856.5	0.1%
VRTX Vertex Pharmaceuticals Inc / Ma	$136.93B	+19.2%	+46.2%	31.5	1.6%
REGN Regeneron Pharmaceuticals, Inc.	$86.39B	+7.1%	+20.8%	20.8	3.3%
MRNA Moderna, Inc.	$69.62B	+352.1%	+4.3%	—	12.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

293

% held: 98.4%
Net QoQ: +9.0M sh
Top holder: T. Rowe Price Investment…

Held Float

View

Held by Funds

Fund positions

279

View

Short & Settlement

Short Interest Rising

Shares short

17.4M

Days to cover: 12.1d
Change: +1.4M sh

View

Short Volume

Short vol %

76%

As of: Aug 20, 2026

Short Total

View

Fails to Deliver

FTD shares

Value: $921
As of: Jul 16, 2026

View

Off-Exchange

Off-exchange %

44.4%

Week of: Jul 13, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$71.6K

Buyers / Sellers: 0 / 1

Buyers Sellers

View

Financials

Revenue (FY)

Net income (FY): $-512.5M
EPS diluted: $-2.97

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 6, 2026
This year: 17

View

Proposed Sales

Value

$801.4K

Shares: 39.5K
Filed: Feb 5, 2026

View

Exempt Offerings

Offering

$499.7M

Filed: Mar 1, 2024

View

Earnings & Events

Earnings Calls

Last call

Aug 6, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
DNLI	+0.5%	+6.5%	+17.8%	+8.4%	+51.1%
SPY	-2.0%	+3.3%	+11.2%	+2.1%	+11.8%
vs SPY	+2.5%	+3.2%	+6.6%	+6.3%	+39.3%

Key facts CIK 1714899 CUSIP 24823R105 13F (30d) 275 filings 268 filers Visit website Investor relations

DNLI · Denali Therapeutics Inc.

Price & Indicators

Up next

Equibles Rating

Guidance & track record

Technicals

Versus peers

At a glance

Performance